NASDAQ:TLSA Tiziana Life Sciences (TLSA) Stock Price, News & Analysis $1.07 +0.18 (+20.22%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.08 +0.01 (+1.40%) As of 04/17/2025 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tiziana Life Sciences Stock (NASDAQ:TLSA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tiziana Life Sciences alerts:Sign Up Key Stats Today's Range$0.87▼$1.1050-Day Range$0.74▼$1.6952-Week Range$0.54▼$1.91Volume366,987 shsAverage Volume458,816 shsMarket Capitalization$125.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.Read More… Tiziana Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreTLSA MarketRank™: Tiziana Life Sciences scored higher than 13% of companies evaluated by MarketBeat, and ranked 902nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Tiziana Life Sciences. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioTiziana Life Sciences has a P/B Ratio of 21.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.05% of the float of Tiziana Life Sciences has been sold short.Short Interest Ratio / Days to CoverTiziana Life Sciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tiziana Life Sciences has recently decreased by 6.94%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTiziana Life Sciences does not currently pay a dividend.Dividend GrowthTiziana Life Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.05% of the float of Tiziana Life Sciences has been sold short.Short Interest Ratio / Days to CoverTiziana Life Sciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tiziana Life Sciences has recently decreased by 6.94%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 2 people have searched for TLSA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows4 people have added Tiziana Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tiziana Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders39.82% of the stock of Tiziana Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Tiziana Life Sciences' insider trading history. Receive TLSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address TLSA Stock News HeadlinesTiziana Life announces dosing at JHU, part of Phase 2 trial of foralumabApril 3, 2025 | markets.businessinsider.comTiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns HopkinsApril 2, 2025 | proactiveinvestors.comNew “Trump” currency proposed in DCFormer Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. April 20, 2025 | Paradigm Press (Ad)Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical TrialApril 2, 2025 | globenewswire.comTiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMSMarch 25, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis TrialMarch 25, 2025 | globenewswire.comTiziana Life Sciences to Present at the 37th Annual Roth ConferenceMarch 17, 2025 | globenewswire.comTiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price RuleMarch 14, 2025 | globenewswire.comSee More Headlines TLSA Stock Analysis - Frequently Asked Questions How have TLSA shares performed this year? Tiziana Life Sciences' stock was trading at $0.6962 at the start of the year. Since then, TLSA shares have increased by 53.7% and is now trading at $1.07. View the best growth stocks for 2025 here. When did Tiziana Life Sciences IPO? Tiziana Life Sciences (TLSA) raised $10 million in an initial public offering on the week of November 19th 2018. The company issued 1,000,000 shares at $9.90 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO. How do I buy shares of Tiziana Life Sciences? Shares of TLSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tiziana Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tiziana Life Sciences investors own include NIO (NIO), Advanced Micro Devices (AMD), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), Inovio Pharmaceuticals (INO) and Pfizer (PFE). Company Calendar Today4/19/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TLSA CIK1723069 Webwww.tizianalifesciences.com Phone44-20-7495-2379FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.85 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book21.40Miscellaneous Outstanding Shares116,848,000Free Float63,427,000Market Cap$125.03 million OptionableOptionable Beta0.54 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:TLSA) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.